Patients with sclerosteosis and van Buchem disease have high bone mass due to downregulation of sclerostin, suggesting that a therapeutic agent that downregulates sclerostin in a controllable fashion might be a potent osteoanabolic treatment for patients with osteoporosis. This evidence concerns the gene SOST and hyperostosis corticalis generalisata.